# Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China

> **NCT02228980** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 602 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
- **BIOLOGICAL:** Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
- **BIOLOGICAL:** Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
- **BIOLOGICAL:** Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation

## Key facts

- **NCT ID:** NCT02228980
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-12
- **Final completion:** 2015-10
- **Target enrollment:** 602 (ACTUAL)
- **Last updated:** 2016-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02228980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02228980, "Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02228980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*